CCL2 and Disorder of lipid metabolism: The results of the present study demonstrated that an appropriate amount of HAS can significantly reduce the serum GSP and GHb levels; significantly increase the INS level in IR model mice; significantly alleviate lipid metabolic disorders in the serum, liver and kidneys; reduce oxidative stress damage in the serum, liver and kidneys of IR model mice; and significantly reduce the levels of inflammatory factors, such as IL-1, IL-6, TNF-α, and MCP-1, in the serum and liver of IR model mice.